TABLE 1

Effect of rosiglitazone treatment on body composition, glycemic control, and plasma lipids levels in type 2 diabetic subjects

Control subjectsDiabetic subjects
P
BeforeRosiglitazone
Body weight (kg)81.1 ± 3.984.1 ± 3.286.5 ± 3.50.0008
BMI (kg/m2)27.3 ± 1.330.5 ± 1.131.4 ± 1.20.0006
Fat mass (kg)23.0 ± 1.827.7 ± 2.030 ± 2.10.0002
HbA1c (%)4.9 ± 0.1*8.5 ± 0.37.1 ± 0.30.0001
Fasting plasma glucose (mg/dl)94 ± 2*185 ± 8139 ± 5<0.0001
Fasting plasma insulin (μU/ml)6 ± 1*16 ± 111 ± 10.002
Fasting C-peptide (ng/ml)1.2 ± 0.31.4 ± 0.21.4 ± 0.3NS
Fasting plasma FFA (μEq/l)625 ± 54789 ± 59646 ± 490.001
Total cholesterol (mg/dl)170 ± 12177 ± 10192 ± 80.08
LDL cholesterol (mg/dl)102 ± 1088 ± 8112 ± 90.009
HDL cholesterol (mg/dl)44 ± 334 ± 238 ± 20.001
Triglycerides (mg/dl)115 ± 28275 ± 83214 ± 530.09
75-g OGTT
 Mean plasma glucose (mg/dl)129 ± 8*290 ± 9225 ± 6<0.0001
 Mean plasma insulin (μU/ml)45 ± 532 ± 429 ± 4NS
 Mean plasma C-peptide (ng/ml)5.3 ± 0.9*2.5 ± 0.43.1 ± 0.3NS
 Mean plasma FFA (μEq/l)398 ± 53*644 ± 41465 ± 34<0.0001
 Insulinogenic index (0–30 min)0.90 ± 0.17*0.17 ± 0.030.21 ± 0.03NS
 Insulinogenic index (0–120 min)2.37 ± 1.31*0.16 ± 0.030.25 ± 0.070.04
  • Data are means ± SE. Comparative data in nondiabetic control subjects also are shown. Insulinogenic index (0–30 min) = Δinsulin/Δglucose from 0 to 30 min during the OGTT. Insulinogenic index (0–120 min) = ΔAUC insulin/ΔAUC glucose from 0 to 120 min during the OGTT.

  • *

    * P < 0.01,

  • P < 0.05 control vs. diabetic subjects before rosiglitazone treatment.